These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 37584173)

  • 1. Optimal timing for therapeutic drug monitoring of voriconazole to prevent adverse effects in Japanese patients.
    Hanai Y; Ueda T; Hamada Y; Oda K; Takahashi Y; Nakajima K; Miyazaki Y; Kiriyama M; Uekusa S; Matsuo K; Matsumoto K; Kimura T; Takesue Y
    Mycoses; 2023 Dec; 66(12):1035-1044. PubMed ID: 37584173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Practice Guideline for the Therapeutic Drug Monitoring of Voriconazole in Non-Asian and Asian Adult Patients: Consensus Review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring.
    Takesue Y; Hanai Y; Oda K; Hamada Y; Ueda T; Mayumi T; Matsumoto K; Fujii S; Takahashi Y; Miyazaki Y; Kimura T;
    Clin Ther; 2022 Dec; 44(12):1604-1623. PubMed ID: 36424314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of antifungal stewardship using therapeutic drug monitoring in voriconazole therapy on the prevention and control of hepatotoxicity and visual symptoms: A multicentre study conducted in Japan.
    Hamada Y; Ueda T; Miyazaki Y; Nakajima K; Fukunaga K; Miyazaki T; Nakada-Motokawa N; Nagao M; Kawamura H; Shigemi A; Ebihara F; Kimura T; Ikegame K; Uchino M; Ikeuchi H; Takesue Y
    Mycoses; 2020 Aug; 63(8):779-786. PubMed ID: 32510723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic drug monitoring of voriconazole in Japanese patients: analysis based on clinical practice data.
    Matsumoto K; Abematsu K; Shigemi A; Kanazawa N; Watanabe E; Yokoyama Y; Ikawa K; Morikawa N; Takeda Y
    J Chemother; 2016 Jun; 28(3):198-202. PubMed ID: 26187373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Voriconazole therapeutic drug monitoring and hepatotoxicity in critically ill patients: A nationwide multi-centre retrospective study.
    Wang T; Miao L; Shao H; Wei X; Yan M; Zuo X; Zhang J; Hai X; Fan G; Wang W; Hu L; Zhou J; Zhao Y; Xie Y; Wang J; Guo S; Jin L; Li H; Liu H; Wang Q; Chen J; Li S; Dong Y
    Int J Antimicrob Agents; 2022; 60(5-6):106692. PubMed ID: 36372345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A retrospective, multicenter study of voriconazole trough concentrations and safety in patients with Child-Pugh class C cirrhosis.
    Wang T; Yan M; Tang D; Xue L; Zhang T; Dong Y; Zhu L; Wang X; Dong Y
    J Clin Pharm Ther; 2018 Dec; 43(6):849-854. PubMed ID: 29893015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The utility of voriconazole therapeutic drug monitoring in a multi-racial cohort in Southeast Asia.
    Zhou PY; Lim TP; Tang SLS; Liew Y; Chua SGN; Lim LLC; Lee HLW; Tan SX; Lai OF; Tan TT; Wong GC; Kwa LHA
    J Glob Antimicrob Resist; 2020 Jun; 21():427-433. PubMed ID: 31846723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Therapeutic Drug Monitoring and Cytochrome P450 2C19 Genotyping on Clinical Outcomes of Voriconazole: A Systematic Review.
    Lee J; Ng P; Hamandi B; Husain S; Lefebvre MJ; Battistella M
    Ann Pharmacother; 2021 Apr; 55(4):509-529. PubMed ID: 32772568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic drug monitoring and safety evaluation of voriconazole in the treatment of pulmonary fungal diseases.
    Shen K; Gu Y; Wang Y; Lu Y; Ni Y; Zhong H; Shi Y; Su X
    Ther Adv Drug Saf; 2022; 13():20420986221127503. PubMed ID: 36225945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a therapeutic drug-monitoring algorithm for outpatients receiving voriconazole: A multicentre retrospective study.
    Kato H; Umemura T; Hagihara M; Shiota A; Asai N; Hamada Y; Mikamo H; Iwamoto T
    Br J Clin Pharmacol; 2024 May; 90(5):1222-1230. PubMed ID: 38320604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of sustained high plasma trough concentration of voriconazole with the incidence of hepatotoxicity.
    Suzuki Y; Tokimatsu I; Sato Y; Kawasaki K; Sato Y; Goto T; Hashinaga K; Itoh H; Hiramatsu K; Kadota J
    Clin Chim Acta; 2013 Sep; 424():119-22. PubMed ID: 23747486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of dose adaptations following voriconazole therapeutic drug monitoring in pediatric patients.
    Lempers VJ; Meuwese E; Mavinkurve-Groothuis AM; Henriet S; van der Sluis IM; Hanff LM; Warris A; Koch BCP; Brüggemann RJ
    Med Mycol; 2019 Nov; 57(8):937-943. PubMed ID: 30759261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Optimized Voriconazole Dosing Strategy to Achieve Therapeutic Serum Concentrations in Children Younger than 2 Years Old.
    Zembles TN; Thompson NE; Havens PL; Kaufman BA; Huppler AR
    Pharmacotherapy; 2016 Oct; 36(10):1102-1108. PubMed ID: 27548272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Investigation and Prediction of Voriconazole-Associated Hepatotoxicity under Therapeutic Drug Monitoring
    Ma J; Wang Y; Ma S; Li J
    Annu Int Conf IEEE Eng Med Biol Soc; 2023 Jul; 2023():1-4. PubMed ID: 38082975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Voriconazole therapeutic drug monitoring in critically ill patients improves efficacy and safety of antifungal therapy.
    Li H; Li M; Yan J; Gao L; Zhou L; Wang Y; Li Q; Wang J; Chen T; Wang T; Zheng J; Qiang W; Zhang Y; Shi Q
    Basic Clin Pharmacol Toxicol; 2020 Dec; 127(6):495-504. PubMed ID: 32639669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using Child-Pugh Class to Optimize Voriconazole Dosage Regimens and Improve Safety in Patients with Liver Cirrhosis: Insights from a Population Pharmacokinetic Model-based Analysis.
    Wang T; Yan M; Tang D; Dong Y; Zhu L; Du Q; Sun D; Xing J; Dong Y
    Pharmacotherapy; 2021 Feb; 41(2):172-183. PubMed ID: 33064889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic drug monitoring-guided treatment versus standard dosing of voriconazole for invasive aspergillosis in haematological patients: a multicentre, prospective, cluster randomised, crossover clinical trial.
    Veringa A; Brüggemann RJ; Span LFR; Biemond BJ; de Boer MGJ; van den Heuvel ER; Klein SK; Kraemer D; Minnema MC; Prakken NHJ; Rijnders BJA; Swen JJ; Verweij PE; Wondergem MJ; Ypma PF; Blijlevens N; Kosterink JGW; van der Werf TS; Alffenaar JC;
    Int J Antimicrob Agents; 2023 Feb; 61(2):106711. PubMed ID: 36642232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Voriconazole therapeutic drug monitoring: results of a prematurely discontinued randomized multicenter trial.
    Neofytos D; Ostrander D; Shoham S; Laverdiere M; Hiemenz J; Nguyen H; Clarke W; Brass L; Lu N; Marr KA
    Transpl Infect Dis; 2015 Dec; 17(6):831-7. PubMed ID: 26346408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Voriconazole trough concentration and hepatotoxicity in patients with low serum albumin
.
    Hirata A; Noto K; Ota R; Yokoyama S; Hosomi K; Takada M; Matsuoka H
    Int J Clin Pharmacol Ther; 2019 Mar; 57(3):135-143. PubMed ID: 30686290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic drug monitoring and safety of voriconazole therapy in patients with Child-Pugh class B and C cirrhosis: A multicenter study.
    Wang T; Yan M; Tang D; Xue L; Zhang T; Dong Y; Zhu L; Wang X; Dong Y
    Int J Infect Dis; 2018 Jul; 72():49-54. PubMed ID: 29793038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.